Clinical value of new techniques of gynecological tumor assessment

International Journal of Gynecological Cancer

Volumn 7, Issue 5, 1997, Pages 337-349

  Fox, H ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID RECEPTOR;

CANCER DIAGNOSIS; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; GENE MUTATION; GYNECOLOGIC CANCER; HUMAN; MORPHOMETRICS; ONCOGENE; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0030716903     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1997.00060.x     Document Type: Review

References (223)

1. van Dam PA, Watson JV, Lowe DG, Shepherd JH. Flow cytometric DNA analysis in gynecological oncology. Int J Gynecol Cancer 1992; 2: 57-65.
2. van Dam PA. Ploidy in ovarian cancer and prognosis. In: Leake R, Gore M, Ward RH, eds. The Biology of Gynaecological Cancer. London: RCOG Press, 1995; 258-273.
3. Kaern J, Iversen T, Trope C, Pettersen EO, Nesland JM. Flow cytometric DNA measurements in squamous cell carcinoma of the vulva: An important prognostic method. Int J Gynecol Cancer 1992; 2: 169-174.
4. Ballouk F, Ambros RA, Malfetano JH, Ross JS. Evaluation of prognostic indicators in squamous carcinoma of the vulva including nuclear DNA content. Mod Pathol 1993; 6: 371-375.
5. Dolan JR, McCall AR, Gooneratne S, Walter S, Lansky DM. DNA ploidy, proliferation index, grade, and stage as prognostic factors for vulvar squamous cell carcinomas. Gynecol Oncol 1993; 48: 232-235.
6. Britton IC, Wilson TO, Gaffey TA, Cha SS, Wieand HS, Podratz KC. DNA ploidy in endometrial carcinoma: Major objective prognostic factor. Mayo Clin Proc 1990; 65: 643-650.
7. Newbury R, Schuerch C, Godspeed N, Fanning J, Glidewell O, Evans M. DNA content as a prognostic factor in endometrial carcinoma. Obstet Gynecol 1990; 76: 251-257.
8. Lindahl B, Gullberg B. Flow cytometrical DNA and clinical parameters in the prediction of prognosis in Stage I-II endometrial cancer. Anticancer Res 1991; 11: 397-401.
9. Dyas CH, Simmons TK, Ellis CM, et al. Effect of desoxyribonucleic acid ploidy status on survival of patients with carcinoma of the endometrium. Surg Gynec Obstet 1992; 174: 133-136.
10. Ikeda M, Watanabe Y, Nanjoh T, Noda K. Evaluation of DNA ploidy in endometrial cancer. Gynecol Oncol 1993; 50: 25-29.
11. Melchiorri C, Chieco P, Lisignoli G, Marabini A, Orlandi C. Ploidy disturbance as an early indicator of intrinsic malignancy in endometrial carcinoma. Cancer 1993; 72: 165-172.
12. Nola M, Babic D, Ilic S, et al. Prognostic parameters for survival in patients with mesenchymal tumors of the uterus. Cancer 1996; 78: 2543-2550.
13. Nordal RR, Kristensen GB, Kaern J, Stenwic AE, Pettersen EO, Trope CG. The prognostic significance of surgery, tumor size, malignancy grade, menopausal status, and DNA ploidy in endometrial stromal sarcoma. Gynecol Oncol 1996; 62: 254-259.
14. Rodenberg CJ, Cornelisse CJ, Heintz PA, Hermans J, Fleuren GJ. Tumor ploidy as a major prognostic factor in advanced ovarian cancer. Cancer 1987; 59: 317-323.
15. Volm M, Kleine W, Pfleiderer A. Flow cytometric prognostic factors for the survival of patients with ovarian carcinoma: A 5 year follow-up study. Gynecol Oncol 1989; 35: 84-89.
16. Klemi PJ, Joensuu H, Naenpaa J, Kiiholma P. Influence of cellular DNA content on survival in ovarian carcinoma. Obstet Gynecol 1989; 74: 200-204.
17. Khoo SK, Hurst T, Kearsley GD, et al. Prognostic significance of tumor ploidy in patients with advanced ovarian cancer. Gynecol Oncol 1990; 39: 284-288.
18. Jakobsen A, Bichel P, Stornes I. Prognostic significance of DNA index in advanced ovarian cancer. Int J Gynecol Cancer 1991; 1: 195-197.
19. Vergote IB, Kaern J, Abeler VM, et al. Analysis of prognostic factors in stage I epithelial ovarian carcinoma: Importance of degree of differentiation and DNA ploidy in predicting relapse. Am J Obstet Gynecol 1993; 169: 40-52.
20. Gajewski WH, Fuller AF, Pastel-Ley C, et al. Prognostic significance of DNA content in epithelial ovarian cancer. Gynecol Oncol 1994; 53: 5-12.
21. Kaern J, Trope CG, Kristensen CB, et al. Evaluation of DNA ploidy and S-phase fraction as prognostic parameters in advanced epithelial ovarian carcinoma. Am J Obstet Gynecol 1994; 170: 479-487.
22. Zanetta G, Keeney GL, Cha SS, Wieand HS, Katzmann JA, Podratz KC. DNA index by flow cytometric analysis: An additional prognostic factor in advanced ovarian carcinoma without residual disease after primary operation. Gynecol Oncol 1996; 62: 208-212.
23. Kigawa J, Minagawa Y, Ishihara H, Kanamori Y, Terakawa N. Tumor DNA ploidy and prognosis of patients with serous cystadenocarcinoma of the ovary. Cancer 1993; 72: 804-808.
24. Pfisterer J, Kommoss F, Sauerbrei A, et al. Cellular DNA content and survival in advanced ovarian cancer. Cancer 1994; 74: 2509-2515.
25. Padberg P-C, Arps H, Franke U, et al. DNA cytophotometry and prognosis in ovarian tumors of borderline malignancy: A clinicopathological study of 80 cases. Cancer 1992; 69: 2510-2514.
26. Kaern J, Trope CG, Kristensen GB, Abeler VM, Pettersen EO. DNA ploidy: The most important prognostic factor in patients with borderline tumors of the ovary. Int J Gynecol Cancer 193; 3: 349-358.
27. Harlow BL, Fuhr JE, McDonald TW, Schwartz SM, Beuerlein FJ, Weiss NS. Flow cytometry as a prognostic indicator in women with borderline epithelial ovarian tumors. Gynecol Oncol 1993; 50: 305-309.
28. Kuoppala T, Heinola M, Aine R, Isola J, Heinonen PK. Serous and mucinous borderline tumors of the ovary: A clinicopathologic and DNA-ploidy study of 102 cases. Int J Gynecol Cancer 1996; 6: 302-308.
29. Sykes P, Quinn M, Rome R. Ovarian tumors of borderline malignancy: A retrospective study of 234 patients. Int J Gynecol Cancer 1997; 7 (in press).
30. Klemi PJ, Joensuu H, Tuala S. Prognostic value of flow cytometric DNA content analysis in granulosa cell tumors of the ovary. Cancer 1990; 65: 1189-1193.
31. Holland DR, Le Riche J, Swenerton KD, Elit L. Flow cytometric assessment of DNA ploidy: A useful prognostic factor for patients with granulosa cell ovarian tumors. Int J Gynecol Cancer 1991; 1: 227-232.
32. Hitchcock CL, Norris HJ, Khalifa MA, Wargotz ES. Flow cytometric analysis of granulosa cell tumors. Cancer 1989; 64: 2127-2132.
33. Swanson SA, Norris HJ, Kelsten ML, Wheeler JE. DNA content of juvenile granulosa cell tumors determined by flow cytometry. Int J Gynecol Pathol 1990; 9: 101-109.
34. Eichhorn JH, Young RH, Scully RE. DNA content and proliferative activity in ovarian small cell carcinomas of the hypercalcemic type: Implications for diagnosis, prognosis and histogenesis. Am J Clin Pathol 1992; 98: 579-586.
35. Davis JR, Aristizabal S, Way DL, Weines SA, Hicks MJ, Hagaman RM. DNA ploidy, grade, and stage in prognosis of uterine cervical cancer. Gynecol Oncol 1989; 32: 4-7.
36. Kenter GG, Cornelisse CJ, Aartsen K, et al. DNA ploidy level as prognostic factor in low stage carcinoma of the uterine cervix. Gynecol Oncol 1990; 39: 181-185.
37. Ji HX, Syrjanen S, Klemi P, Chang F, Tosi P, Syrjanen K. Prognostic significance of human papillomavirus (HPV) type and nuclear DNA content in invasive cervical cancer. Int J Gynecol Cancer 1991; 1: 59-67.
38. Strang P, Stendhal U, Bergstrom R, Frankendal B, Tribuait R. Prognostic flow cytometric information in cervical squamous cell carcinoma: A multivariate analysis of 307 patients. Gynecol Oncol 1991; 43: 3-8.
39. Zanetta GM, Katzmann JA, Keeney GL, Kinney WK, Cha SS, Podratz KC. Flow-cytometric DNA analysis of stages IB and IIA cervical carcinoma. Gynecol Oncol 1992; 46: 13-19.
40. Jarrell MA, Heintz N, Howard P, et al. Squamous cell carcinoma of the cervix: HPV 16 and DNA ploidy as predictors of survival. Gynecol Oncol 1992; 46: 361-366.
41. Connor JP, Miller DS, Bauer KD, Murad TM, Rademaker AW, Lurain JR. Flow cytometric evaluation of early invasive cervical cancer. Obstet Gynecol 1993; 81: 367-371.
42. Pfisterer J, Kommoss F, Sauerbrei W, et al. DNA flow cytometry in stage IB and II cervical carcinoma. Int J Gynecol Cancer 1996; 6: 54-60.
43. Putten HWHM, Baak JPA, Koenders TJM, et al. Prognostic value of quantitative pathologic features and DNA content in individual patients with stage I endometrial adenocarcinoma. Cancer 1989; 63: 1378-1387.
44. Sorbe B, Risberg B, Thornthwaite J. Nuclear morphometry and DNA flow cytometry as prognostic methods for endometrial carcinoma. Int J Gynecol Cancer 1994; 4: 94-100.
45. Baak JPA, Langley FA, Talerman A, Delemarre JFM. Morphometric data in the prognosis of ovarian tumours in addition to FIGO stage, histologic type and grade. J Clin Pathol 1986; 39: 1340-1346.
46. Baak JPA, Wisse-Brekelmans ECM, Uyterlinde AM, Schipper NW. Evaluation of the prognostic value of morphometric features and cellular DNA content in FIGO 1 ovarian cancer patients. Anal Quant Cytol Histol 1987; 9: 287-290.
47. Baak JPA, Schipper NW, Wisse-Brekelmans ECM, et al. The prognostic value of morphometrical features and cellular DNA content in cis-platin treated late ovarian cancer patients. Br J Cancer 1988; 57: 503-508.
48. Haapasalo H, Collan Y, Atkin NB, Personen E, Seppa A. Prognosis of ovarian carcinomas: Prediction by histoquantitative methods. Histopathology 1989; 15: 167-178.
49. Schipper NW, Smeulders AWM, Baak JPA. Evaluation of automated estimation of epithelial volume and its prognostic value in ovarian tumors. Lab Invest 1989; 61: 228-234.
50. Haapasalo H, Collan Y, Seppa A, et al. Prognostic value of ovarian carcinoma grading methods: a method comparison study. Histopathology 1990; 16: 1-7.
51. Diest PJ van, Baak JPA, Brugghe J, et al. Quantitative prognostic features as predictors of long-term survival in patients with advanced ovarian cancer treated with cisplatin. Int J Gynecol Cancer 1994; 3: 74-180.
52. Ludescher C, Weger AR, Lindholm J, et al. Prognostic significance of tumor cell morphometry, histopathology, and clinical parameters in advanced ovarian carcinoma. Int J Gynecol Pathol 1990; 9: 343-351.
53. Hogberg T, Wang G, Risberg B, et al. Nuclear morphometry: A strong prognostic factor for survival after secondary surgery in advanced ovarian cancer. Int J Gynecol Cancer 1992; 2: 198-206.
54. Brinkhuis M, Baak JPA, Diest PA van, Lund B, Wils J. In Dutch and Danish patients with FIGO III ovarian carcinoma, geographic survival differences are associated with differences in quantitative pathologic features. Int J Gynecol Cancer 1996; 6: 108-114.
55. Brinkhuis M, Lund B, Meijer GA, Bak JPA. Quantitative pathologic variables as prognostic factors for overall survival in Danish patients with FIGO stage III ovarian cancer. Int J Gynecol Cancer 1996; 6: 168-174.
56. Bjerregaard B, Andreasson B, Visfeldt J, Bock JE. The significance of histology and morphometry in predicting lymph node metastases in patients with squamous cell carcinoma of the vulva. Gynecol Oncol 1993; 50: 323-329.
57. Budwit-Novotny DA, McCarty KS, Cox EB, et al. Immunohistochemical analysis of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res 1986; 46: 5419-5425.
58. Carcangiu ML, Chambers JT, Voynick IM, Pirro M, Schwartz PE. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Am J Clin Pathol 1990; 94: 247-254.
59. Chambers JT, Carcangiu ML, Voynick IM, Schwartz PE. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. II. Correlation between biochemical and immunohistological methods and survival. Am J Clin Pathol 1990; 34: 255-260.
60. Snijders MP, de-Goeij AF, Koudstaal J, et al. Is immunohistochemical analysis of oestrogen and progesterone receptors in endometrial carcinoma superior to the radioligand binding assay? J Pathol 1990; 161: 129-135.
61. Aasmundstad TA, Haugen OA, Johannesen E, Hoe AL, Kvinsland S. Oestrogen receptor analysis: Correlation between enzyme immunoassay and immunohistochemical methods. J Clin Pathol 1992; 43: 125-129.
62. Nyholm HCJ, Nielsen AL, Lyndrup J, Dreisler A, Thorpe SM. Estrogen and progesterone receptors in endometrial carcinoma: Comparison of immunohistochemical and biochemical analysis. Int J Gynecol Pathol 1993; 12: 246-252.
63. Chambers JT. Sex steroid receptors in endometrial cancer. Yale J Biol Med 1988; 61: 339-350.
64. Huang SJ, Cheng L, Lewin KJ, Fu YS. Immunohistochemical estrogen receptor assessment in hyperplastic, neoplastic, and physiologic endometria. Path Res Prac 1991; 187: 487-495.
65. Creasman W, Soper JT, McCarty JS, Jr, et al. Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am J Obstet Gynecol 1985; 131: 922-932.
66. Ehrlich CE, Young PC, Stehman FB, Sutton GP, Alford WM. Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol 1988; 158: 796-807.
67. Ingram SS, Rosenman J, Heath R, Morgan TM, Moore D, Varia M. The predictive value of progesterone receptor levels in endometrial cancer. Int J Radiat Oncol Biol Phys 1989; 17: 21-27.
68. Borazjani G, Twiggs LB, Leung BS, Prem KA, Adcock LL, Cardon LF. Prognostic significance of steroid receptors measured in primary, metastatic and recurrent endometrial carcinoma. Am J Obstet Gynecol 1989; 161: 1253-1257.
69. Segreti EM, Novotny DB, Soper JT, Mutch DG, Creasman WT, McCarty KS. Endometrial cancer: Histologic correlates of immunohistochemical localization of progesterone receptor and estrogen receptor. Obstet Gynecol 1989; 73: 780-785.
70. Tornos C, Silva EG, el Naggar A, Burke TW. Aggressive stage I grade I endometrial carcinoma. Cancer 1992; 70: 790-798.
71. Creasman WT. Prognostic significance of hormone receptors in endometrial cancer. Cancer 1993; 71: 287-288.
72. Pertschuk LP, Masood S, Simone J. Estrogen receptor immunocytochemistry in endometrial carcinoma: A prognostic marker of survival. Gynecol Oncol 1996; 63: 28-33.
73. Kerner H, Sabo E, Friedman M, Beck D, Samare O, Lichtig C. An immunohistochemical study of estrogen and progesterone receptors in adenocarcinoma of the endometrium and in the adjacent mucosa. Int J Gynecol Cancer 1995; 8: 275-281.
74. Bizzi A, Codegoni AM, Landoni F, et al. Steroid receptors in epithelial ovarian carcinoma: Relation to clinical parameters and survival. Cancer Res 1988; 48: 6222-6226.
75. Rose PJ, Reale FR, Longcope C, Hunter RE. Prognostic significance of estrogen and progesterone receptors in ovarian epithelial cancer. Obstet Gynecol 1990; 76: 258-263.
76. Sevelda P, Denison U, Schemper M, et al. Oestrogen and progesterone receptor content as a prognostic factor in advanced epithelial ovarian carcinoma. Br J Obstet Gynaecol 1990; 97: 706-712.
77. Slotman BJ, Narta JJP, Rao BR. Survival of patients with ovarian cancer: Apart from stage and grade, tumor progesterone receptor content is a prognostic indicator. Cancer 1990; 66: 740-744.
78. Leake RE, Owens O. The prognostic value of steroid receptors, growth factors and growth factor receptors in ovarian cancer. In: Sharp F, Mason WP, Leake RE, eds. Ovarian Cancer: Biological and Therapeutic Challenges. London: Chapman and Hall, 1990; 69-75.
79. Hunter RE, Longcope C, Keough P. Steroid hormone receptors in carcinoma of the cervix. Cancer 1987; 60: 392-396.
80. Harding M, McIntosh J, Paul M, et al. Oestrogen and progesterone receptors in carcinoma of the cervix. Clin Oncol 1990; 2: 313-317.
81. Darne J, Soutter WP, Ginsberg R, Sharpe F. Nuclear and "cytoplasmic" estrogen and progesterone receptors in squamous cell carcinoma of the cervix. Gynecol Oncol 1990; 38: 216-219.
82. Scott RJ, Hall PA, Haldane JS, et al. A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction. J Pathol 1991; 165: 173-178.
83. Hall PA, Levison DA. Assessment of cellular proliferation in histological material. J Clin Pathol 1990; 43: 184-192.
84. McCormick D, Chong H, Hobbs C, Datta C, Hall PA. Detection of the Ki67 antigen in fixed and wax embedded sections with the monoclonal antibody MIB1. Histopathology 1993; 22: 355-360.
85. Konishi I, Jujii S, Nonogaki H, Nanbu Y, Iwai T, Mori T. Immunohistochemical analysis of estrogen receptors, progesterone receptors, Ki-67 antigen, and human papillomavirus DNA in normal and neoplastic epithelium of the uterine cervix. Cancer 1991; 68: 1340-1350.
86. Shurbaji MS, Brooks SK, Thurmond TS. Proliferating cell nuclear antigen: Immunoreactivity in cervical intraepithelial neoplasia and benign cervical epithelium. Am J Clin Pathol 1993; 100: 22-26.
87. Mittal KR, Demopoulos RJ, Goswami S. Proliferating cell nuclear antigen (cyclin) expression in normal and abnormal squamous epithelia. Am J Surg Pathol 1993; 17: 117-122.
88. Raju GC. Expression of the proliferating cell nuclear antigen in cervical neoplasia. Int J Gynecol Pathol 1994; 13: 337-341.
89. McLuggage WG, Buhidma M, Tang L, Maxwell P, Bharucha H. Monoclonal antibody MIB1 in the assessment of cervical squamous intraepithelial lesions. Int J Gynecol Pathol 1996; 15: 131-136.
90. Hoeven KH van, Kovatich AJ. Immunohistochemical staining for proliferating cell nuclear antigen, BCL2, and Ki-67 in vulvar tissues. Int J Gynecol Pathol 1996; 15: 10-16.
91. Oka K, Hoshi T, Arai T. Prognostic significance of the PC10 index as a prospective assay for cervical cancer treated with radiation therapy alone. Cancer 1992; 70: 1545-1550.
92. Al-Nafussi AI, Klys HS, Rebello G, Kelly C, Kerr G, Cowie V. The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in the uterine cervix and cervical squamous neoplasia. Int J Gynecol Cancer 1993; 3: 154-158.
93. Cole DJ, Brown DC, Crossley F, Alcock CJ, Gatter KC. Carcinoma of the cervix uteri: An assessment of the relationship of tumour proliferation to prognosis. Br J Cancer 1992; 65: 783-785.
94. Levine EL, Renehan A, Gossiel R, et al. Apoptosis, intrinsic radiosensitivity and prediction of radiotherapy response in cervical carcinoma. Radiother Oncol 1995; 37: 1-9.
95. Oka K, Arai T. MIB1 growth fraction is not related to prognosis in cervical squamous cell carcinoma treated with radiotherapy. Int J Gynecol Pathol 1996; 15: 23-27.
96. Garzetti GG, Ciavittini A, Lucarini G, et al. MIB1 immunostaining in stage 1 squamous cervical carcinoma: relationship with natural killer cell activity. Gynecol Oncol 1995; 58: 28-33.
97. Garzetti GG, Ciavattini A, Goteri G, et al. Proliferating cell nuclear antigen (PCNA) immunoreactivity in stage I endometrial cancer: A new prognostic factor. Int J Gynecol Cancer 1996; 6: 186-192.
98. Garzetti CG, Ciavattini A, Goteri G, de Nictolis M, Romanini G. Proliferating cell nuclear antigen in endometrial adenocarcinoma: Pre-treatment identification of high risk patients. Gynecol Oncol 1996; 61: 16-21.
99. Nielsen AL, Nyholm HCJ, Engel P. Expression of MIB-1 (paraffin ki-67) and AgNOR morphology in endometrial adenocarcinomas of endometrioid type. Int J Gynecol Pathol 1994; 13: 37-44.
100. Geisler JP, Wiemann MC, Zhou Z, Miller CA, Geisler HE. Proliferation index determined by MIB-1 and recurrence of endometrial carcinoma. Gynecol Oncol 1996; 61: 373-377.
101. Hamel NW, Sebo TJ, Wilson TO, et al. Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma. Gynecol Oncol 1996; 62: 192-198.
102. Nordstrom B, Strang P, Bergstrom R, Nilsson S, Tribukait B. A comparison of proliferation markers and their prognostic value for women with endometrial carcinoma: Ki-67, proliferating cell nuclear antigen and flow cytometric S-phase factor. Cancer 1996; 78: 1942-1951.
103. Hendricks JB, Wilkinson EJ, Kubilis P, Drew P, Blaydes SM, Munakata S. Ki-67 expression in vulvar carcinoma. Int J Gynecol Pathol 1994; 13: 205-210.
104. Guo L-N, Wilkinson N, Buckley CH, Fox H, Hale RJ, Chawner L. Proliferating cell nuclear antigen (PCNA) immunoreactivity in ovarian serous and mucinous neoplasms: Diagnostic and prognostic value. Int J Gynecol Cancer 1993; 3: 391-394.
105. Isola J, Kallioniemi O-P, Korte J-M, et al. Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: Correlation with DNA flow cytometry, biochemical receptor assay, and patient survival. J Pathol 1990; 162: 295-301.
106. Kerns BM, Jordan PA, Faerman LL, Berchuck A, Bast RC. Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis. Am J Clin Pathol 1994; 101: 192-197.
107. Hendriksen R. Ovarian Carcinogenesis: A Study of Markers for Growth Regulatory Mechanisms in Epithelial Ovarian Tumors. Uppsala, Sweden: University of Uppsala, 1994, pp. Dissertation.
108. de Nictolis M, Garbisa S, Lucarini G, et al. 72 kilo-dalton type IV collagenase, type IV collagen, and Ki67 in serous tumors of the ovary: A clinicopathologic, immunohistochemical, and serological study. Int J Gynecol Pathol 1996; 15: 102-109.
109. Inoue M, Fujita M, Enomoto T, et al. Immunohistochemical analysis of p53 in gynecologic tumors. Am J Clin Pathol 1994; 102: 665-670.
110. Levine AJ, Momand J, Finley CA. The p53 tumour suppressor gene. Nature 1991; 351: 453-456.
111. Dowell SP, Hall PA. The clinical relevance of the p53 tumour suppression gene. Cytopathology 1994; 5: 133-145.
112. Wynford-Thomas D. p53 in tumour pathology: Can we trust immunocytochemistry? J Pathol 1992; 166: 329-330.
113. Marks JR, Davidoff AM, Kerns BJ, et al. Overexpression and mutation of p53 in epithelial ovarian cancer Cancer Res 1991; 51: 2979-2984.
114. Eccles DM, Brett L, Lessells A, et al. Overexpression of the p53 protein and allelic loss of 17p13 in ovarian carcinoma. Br J Cancer 1992; 65: 40-44.
115. Kupryjanczyk J, Thor AD, Beauchamp R, et al. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 1993; 90: 4961-4965.
116. Kohler MF, Marks JR, Wiseman RW, et al. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 1993; 85: 1513-1519.
117. Milner BJ, Allan LA, Eccles DM, et al. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993; 53: 2128-2132.
118. Kiyokawa T. Alteration of p53 in ovarian cancer: Its occurrence and maintenance in tumor progression. Int J Gynecol Pathol 1994; 13: 311-318.
119. Henriksen R, Strang P, Wilander E, Backstrom T, Tribukait B, Oberg K. p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol Oncol 1994; 53: 301-306.
120. Niwa K, Itoh M, Murase T, et al. Alteration of p53 gene in ovarian carcinoma: Clinicopathological correlation and prognostic significance. Br J Cancer 1994; 70: 1191-1197.
121. McManus DT, Yep EPH, Maxwell P, Russell SEH, Toner PG, McGee JO'D. p53 expression, mutation and allelic deletion in ovarian cancer. J Pathol 1994; 174: 159-168.
122. Hutson R, Ramsdale J, Wells M. p53 protein expression in putative precursor lesions of epithelial ovarian cancer. Histopathology 1995; 27: 367-371.
123. Kupryjanczyk J, Bell DA, Yandell DW, Scully RE, Thor AD. p53 expression in ovarian borderline tumors and Stage 1 carcinomas. Am J Clin Pathol 1994; 102: 671-676.
124. Levesque MA, Katsaros D, Yu H, et al. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995; 75: 1327-1338.
125. Klemi PJ, Takahashi S, Joensuu H, Kiiholma P, Narimatsu E, Mori M. Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumors. Int J Gynecol Pathol 1994; 13: 228-233.
126. Hartmann LC, Podratz KC, Keeney GL, et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 1994; 12: 64-69.
127. Allan LA, Campbell MK, Eccles RCF, et al. The significance of p53 mutation and over-expression in ovarian cancer prognosis. Int J Gynecol Cancer 1996; 6: 483-490.
128. Wertheim I, Muto MG, Welch WR, Bell DA, Berkowitz RS, Mok SC. p53 gene mutation in human borderline epithelial ovarian tumors. J Natl Cancer Inst 1994; 86: 1549-1551.
129. Berchuck A, Kohler M, Hopkins MP, et al. Overexpression of p53 is not a feature of benign and early stage borderline epithelial ovarian tumors. Gynecol Oncol 1994; 52: 232-236.
130. Marcelli AR, Demopoulos RI, Goswami S, Mittal KR. Comparison of p53 and MIB1 expression in benign and borderline areas of ovarian serous tumors. Int J Gynecol Pathol 1996; 15: 39-44.
131. Eltabbakh GH, Belinson JL, Kennedy AW, Biscotti CV, Casey G, Tubbs RR. p53 and HER-2/neu overexpression in ovarian borderline tumors. Gynecol Oncol 1997; 65: 218-224.
132. Khalifa MA, Mannel RS, Haraway SD, et al. Expression of EGFR, HER/2-neu, p53 and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol 1994; 53: 84-92.
133. Inoue M, Okayama A, Fujita M, et al. Clinicopathological characteristics of p53 over-expression in endometrial cancers. Int J Cancer 1994; 58: 14-19.
134. Prat J, Oliva E, Lerma E, Vaquero M, Matiasguiu X. Uterine papillary serous adenocarcinoma: A 10-case study of p53 and c-erb-B2 expression and DNA content. Cancer 1994; 74: 1773-1783.
135. Kohler MF, Berchuck A, Davidoff AM, et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 1992; 52: 1622-1627.
136. Yu CC-W, Wilkinson N, Brito MJ, et al. Patterns of immunohistochemical staining for proliferating nuclear antigen and p53 in benign and neoplastic human endometrium. Histopathology 1993; 23: 367-371.
137. Ito K, Watanabe K, Nasim S, et al. Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res 1994; 54: 4667-4670.
138. Pisani AL, Barbuto DK, Chen D, Ramos L, Lagasse LD, Karlan BY. HER-2/neu, p53 and DNA analysis as prognosticators for survival in endometrial carcinoma. Obstet Gynecol 1995; 85: 729-734.
139. Kohlberger P, Gitsch G, Loesch A, Reinthaler A, Kainz C, Breiteneker G. p53 protein overexpression in early stage endometrial carcinoma. Gynecol Oncol 1996; 62: 213-217.
140. Sorbe B, Risberg B. Prognostic importance of the nuclear proteins p53 and Rb in conjunction with DNA, nuclear morphometry and grading in endometrial carcinoma. Int J Gynecol Cancer 1997; 7: 34-41.
141. Tsuda H, Hirohasi S. Frequent occurrence of p53 gene mutations in uterine cancers at advanced clinical stage and with aggressive histological phenotypes. Jpn J Cancer Res 1992; 83: 1184-1191.
142. Hachisuga T, Fukuda K, Uchiyama M, Matsuo N, Iwasaka T, Sugimori H. Immunohistochemical study of p53 expression in endometrial carcinomas: Correlation with markers of proliferating cells and clinicopathologic features. Int J Gynecol Cancer 1993; 3: 363-368.
143. Reinartz JJ, George E, Lindgren BR, Niehans GA. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum Pathol 1994; 25: 1075-1083.
144. Nielson AL, Nyholm HCJ. p53 protein and c-erbB-2 protein (p185) in endometrial adenocarcinoma of endometrioid type: An immunohistochemical examination on paraffin sections. Am J Clin Pathol 1994; 102: 76-79.
145. Lukes AS, Kohler MF, Pieper CF, et al. Multivariate analysis of DNA ploidy, p53 and HER-2/neu as prognostic factors in endometrial carcinoma. Cancer 1994; 73: 2380-2385.
146. Scheffner M, Werness BA, Huibregate JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-1136.
147. Crook T, Wrede D, Tidy JA, Mason WP, Evans DJ, Vousden KH. Clonal p53 mutation in primary cervical cancer: Association with human-papillomavirus-negative tumours. Lancet 1992; 330: 1070-1073.
148. Tidy JA, Wrede D. Tumor suppression genes: New pathways in gynecological cancer. Int J Gynecol Cancer 1993; 2: 1-8.
149. Riou G, Favre M, Jeannel D, Bourhis J, Le Doussal V, Orth G. Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA. Lancet 1990; 335: 1171-1174.
150. Higgins GD, Davy M, Roder D, Uzelin DM, Phillips GE, Burrell CJ. Increased age and mortality associated with cervical carcinoma negative for human papillomavirus RNA. Lancet 1991; 338: 910-913.
151. Fujita M, Inoue M, Tanizawa O, Iwamoto S, Enomoto T. Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection. Cancer Res 1992; 52: 5323-5328.
152. Srivastava S, Tong YA, Devadas K, et al. The status of the p53 gene in human papilloma virus positive or negative cervical carcinoma cell lines. Carcinogenesis 1992; 12: 1273-1275.
153. Isuda S, Hirohashi S. Frequent occurrence of p53 gene mutations in uterine cancers at advanced clinical stage and with aggressive histological phenotypes. Jpn Cancer Res 1992; 83: 1184-1191.
154. Choo KB, Chong KY. Absence of mutation in the p53 and retinoblastoma susceptibility genes in primary cervical carcinomas. Virology 1993; 193: 1042-1046.
155. Isawaka T, Oh-Uchida M, Matsuo N, et al. Correlation between HPV positivity and state of the p53 gene in cervical carcinoma cell lines. Gynecol Oncol 1993; 48: 104-109.
156. Busby-Earle RMC, Steel CM, Williams ARW, Cohen B, Bird CC. p53 mutations in cervical carcinogenesis: Low frequency and lack of correlation with human papilloma status. Br J Cancer 1994; 69: 732-737.
157. Lee JH, Kang YS, Koh JW, et al. p53 gene mutation is rare in human cervical carcinomas with positive HPV sequences. Int J Gynecol Cancer 1994; 4: 371-378.
158. Jeffers MD, Richmond J, Farquharson M, Menicol M. p53 immunoreactivity in cervical intraepithelial neoplasia and non-neoplastic cervical squamous epithelium. J Clin Pathol 1994; 47: 1073-1076.
159. Miwa K, Miyamoto S, Kato H, et al. The role of p53 inactivation in human cervical cell carcinoma development. Br J Cancer 1995; 71: 219-226.
160. Chetty R, Bramdev A, Aguirre-Arteta A, Pegoraro RJ, Sataar N. Relation between retinoblastoma and p53 proteins in human papilloma viruses 16/18 positive and negative cancers of the uterine cervix. J Clin Pathol 1997; 50: 413-416.
161. Harmsel ter B, Belkum A van, Quint W, et al. p53 and human papilloma virus type 16 in cervical intraepithelial neoplasia and carcinoma. Int J Gynecol Pathol 1995; 14: 125-133.
162. Hellstrom AC, Hue J, Silfversward C, Auer G. DNA-ploidy and mutant p53 overexpression in primary fallopian tube cancer. Int J Gynecol Cancer 1994; 4: 408-413.
163. Zheng W, Sung CJ, Cao P, et al. Early occurrence and prognostic significance of p53 expression in primary carcinoma of the Fallopian tube. Gynecol Oncol 1997; 64: 38-48.
164. Kohlberger P, Kainz C, Breitenecker G, et al. Prognostic value of immunohistochemically detected p53 expression in vulvar carcinoma. Cancer 1995; 76: 1786-1789.
165. Sliutz G, Schmidt W, Tempfer C, et al. Detection of p53 point mutation in primary human vulvar cancer by PCR with temerature gradient gel electrophoresis. Gynecol Oncol 1997; 64: 93-98.
166. Kagie MJ, Kenter GG, Tollenaar RAEM, Hermans J, Trimbos JB, Fleuren GJ. p53 protein overexpression, a frequent observation in squamous cell carcinoma of the vulva and in various synchronous vulvar epithelia, has no value as a prognostic parameter. Int J Gynecol Pathol 1997; 16: 124-130.
167. Watson JV, Curling OM, Hudson CN. Flow cytometric quantitation of p62myc and DNA in serous papillary ovarian cancer. In: Sharp F, Mason WP, Leake RE, eds. Ovarian Cancer: Biological and Therapeutic Challenges. London: Chapman & Hall, 1990; 123-138.
168. Sasano H, Nagura H, Silverberg SG. Immunolocalization of c-myc oncoprotein in mucinous and serous adenocarcinomas of the ovary. Hum Pathol 1992; 23: 491-495.
169. Polocarz SV, Hey NA, Stephenson TJ, Hill AS. c-myc oncogene product P62c-myc in ovarian mucinous neoplasms: immunohistochemical study correlated with malignancy. J Clin Pathol 1990; 42: 896-899.
170. Bauknecht T, Bermelin G, Kommoss F. Clinical significance of oncogenes and growth factors in ovarian carcinoma. J Steroid Biochem Med Biol 1990; 37: 855-862.
171. Beckmann MW, An HX, Niederacher D, Kohrer K, Finken-Eigen M, Schroder W, et al. Oncogene amplification in archival ovarian carcinoma detected by fluorescent differential polymerase chain reaction - A routine analytical approach. Int J Gynecol Cancer 1996; 6: 291-297.
172. van Dam PA, Vergote IB, Lowe DG, et al. Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor1, and epidermal growth factor receptor in ovarian carcinoma. J Clin Pathol 1994; 47: 914-919.
173. Park JS, Kim HK, Han SK, Lee JM, Namkoong SE, Kim SJ. Detection of c-K-ras point mutation in ovarian cancer. Int J Gynecol Cancer 1995; 5: 107-111.
174. Yaginuma Y, Yamashita K, Kuzumaki N, et al. ras oncogene product p21 expression and prognosis of human ovarian tumors. Gynecol Oncol 1992; 46: 45-50.
175. Scambia G, Catozzi L, Panici PB, et al. Expression of ras p21 protein in normal and neoplastic ovarian tissues: Correlation with histopathologic features and receptors for estrogen, progesterone, and epidermal growth factor. Amer J Obstet Gynecol 1993; 168: 71-78.
176. Leeson SC, Morphopoulos G, Buckley CH, Hale RJ. c-erbB2 oncogene expression in stage 1 epithelial ovarian cancer. Br J Obstet Gynaecol 1995; 102: 65-67.
177. Felip E, Del Campo JM, Rubio D, Vidal MT, Colomer R, Bermejo B. Overexpression of c-erbB-2 in epithelial ovarian cancer. Cancer 1995; 75: 2147-2152.
178. Berchuck A, Kamel A, Whitaker R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990; 50: 4087-4091.
179. Meden H, Marx D, Rath W, et al. Overexpression of the oncogene c-erbB-2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol 1994; 13: 45-53.
180. Haldane JS, Hird V, Hughes CM, Gullick WJ. c-erbB-2 oncogene expression in ovarian cancer. J Pathol 1990; 162: 231-237.
181. Wilkinson N, Todd N, Buckley CH, Gusterson BA, Fox H. An immunohistochemical study of the incidence and significance of c-erbB-2 oncoprotein overexpression in ovarian neoplasia. Int J Gynecol Cancer 1991; 1: 285-289.
182. Rubin SC, Finstad CL, Wong GY, et al. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: A multivariate analysis. Amer J Obstet Gynecol 1993; 168: 162-169.
183. Rubin SC, Finstad CL, Federici MG, et al. Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer. Cancer 1994; 73: 1456-1459.
184. Singleton TP, Perrone T, Oakley G, et al. Activation of c-erbB-2 and prognosis in ovarian carcinoma. Cancer 1994; 73: 1460-1466.
185. Makar AP, Holm R, Kristensen GB, Nesland JM, Trope CG. The expression of c-erbB-2 (HER-2/neu) oncogene in invasive ovarian malignancies. Int J Gynecol Cancer 1994; 4: 194-199.
186. Monk BJ, Chapman JA, Johnson GA, et al. Correlation of c-myc and HER-2/neu amplification and expression with histopathologic variables in uterine corpus cancer. Am J Obstet Gynecol 1994; 171: 1193-1198.
187. Sato S, Ito K, Ozawa N, et al. Expression of c-myc, epidermal growth factor receptor and c-erbB-2 in human endometrial carcinoma and cervical adenocarcinoma. Tohoku J Exp Med 1991; 165: 137-145.
188. Bai MK, Costopoulos JS, Christofiridou BP, Papadimitrou CS. Immunochemical detection of the c-myc oncogene product in normal, hyperplastic and carcinomatous endometrium. Oncology 1994; 51: 314-319.
189. Boyd J, Risinger JL. Analysis of oncogene alterations in human endometrial carcinoma: Prevalence of ras mutations. Mol Carcinog 1991; 4: 189-195.
190. Enomoto T, Inoue M, Perantoni AO, et al. k-ras activation in premalignant and malignant epithelial lesions of the human uterus. Cancer Res 1991; 51: 5308-5314.
191. Enomoto T, Fujita M, Inoue M, et al. Alterations of the p53 tumor suppressor gene and its association with activation of the c-k-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. Cancer Res 1993; 53: 1883-1888.
192. Caduff RF, Johnston CM, Frank TS. Mutations of the Ki-ras oncogene in carcinoma of the endometrium. Am J Pathol 1995; 146: 182-188.
193. Tsuda H, Jiko K, Yajima M, et al. Frequent occurrence of ci-k-ras gene mutations in well differentiated endometrial adenocarcinoma showing infiltrative local growth with fibrosing stromal response. Int J Gynecol Pathol 1995; 14: 255-259.
194. Scambia G, Catozzi L, Benedetti-Panici P, et al. Expression of ras p21 oncoprotein in normal and neoplastic human endometrium. Gynecol Oncol 1993; 50: 339-346.
195. Ito K, Watanabe K, Karim S, et al. k-ras point mutation in endometrial carcinoma: Effect on outcome is dependent on age of patients. Gynecol Oncol 1996; 63: 238-246.
196. Milde-Langosch K, Wickens V, Brack T, Loning T. Nachweis und biologische Bedeutung von Viren und Onkogenen bei Uteruskarzinomen. Verh Dtsch Ges Pathol 1991; 75: 363-365.
197. Hetzel DJ, Wilson TO, Keeney GL, et al. HER-2/neu expression: A major prognostic factor in endometrial cancer. Gynecol Oncol 1992; 47: 179-185.
198. Wang D, Konishi I, Koshiyama M, et al. Expression of c-erbB-2 protein and epidermal growth factor receptor in endometrial carcinomas: Correlation with clinico-pathologic and sex steroid receptor status. Cancer 1993; 72: 2628-2637.
199. Khalifa MA, Marmel RS, Haraway SD, Walker J, Min KW. Expression of EGFR, HER-2/neu, p53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol 1994; 53: 84-92.
200. Czerwenka K, Lu Y, Heuss F. Amplification and expression of the c-erbB-2 oncogene in normal, hyperplastic and malignant endometria. Int J Gynecol Pathol 1995; 14: 98-106.
201. Prat J, Oliva E, Lerma E, Vaquero M, Matias Guiu X. Uterine papillary serous adenocarcinoma: A 10-case study of p53 and c-erbB-2 expression and DNA content. Cancer 1994; 74: 1778-1783.
202. Pisani AL, Barbuto DA, Chen D, Ramos L, Lagasse LD, Karlan BY. HER-2/neu, p53 and DNA analyses as prognosticators for survival in endometrial carcinoma. Obstet Gynecol 1995; 85: 729-734.
203. Reinartz JJ, George E, Lindgren BR, Niehans GA. Expression of p53, transforming growth alpha, epidermal growth factor receptor and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of surbival. Hum Pathol 1994; 25: 1075-1083.
204. Santini D, Ceccarelli C, Martinelli GN, et al. Immunocytochemical study of epidermal growth factor receptor, transforming growth factor alpha, and "squamous differentiation" in human endometrial carcinoma. Hum Pathol 1994; 25: 1319-1323.
205. Ocadiz R, Sauceda R, Cruz M, Graef AM, Gariglio P. High correlation between molecular alterations of the c-myc oncogene and carcinoma of the uterine cervix. Cancer Res 1987; 47: 4173-4177.
206. Kohler M, Janz I, Wintzer HO, Wagner E, Bauknecht T. The expression of EGF receptors, EFF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance. Anticancer Res 1989; 9: 1537-1547.
207. Riou G, Barrois M, Le MG, George M, Doussal VL, Haie C. c-myc proto-oncogene expression and prognosis in early carcinoma of the uterine cervix. Lancet 1987; i: 761-763.
208. Sowani A, Ong G, Dische S, et al. c-myc oncogene expression and clinical outcomes in carcinoma of the cervix. Mol Cell Probes 1989; 3: 117-123.
209. Bourhis J, Le MG, Barrois M, et al. Prognostic value of c-myc-proto-oncogene overexpression in early invasive carcinoma of the cervix. J Clin Oncol 1990; 8: 1789-1796.
210. Riou G, Bourhis J, Le GM. The c-myc proto-oncogene in invasive carcinomas of the uterine cervix: Clinical relevance of overexpression in early stages of the cancer. Anticancer Res 1990; 10: 1225-1231.
211. Iwasaka T, Yokoyama M, Oh-Uchida M, et al. Detection of human papillomavirus genome and analysis of c-myc and Ha-ras oncogenes in invasive cervical carcinomas. Gynecol Oncol 1992; 46: 298-303.
212. Symonds RP, Habeshaw T, Paul J, et al. No correlation between ras, c-myc and c-jun proto-oncogene expression and prognosis in advanced carcinoma of the cervix. Eur J Cancer 1992; 28A: 1616-1617.
213. Falcinelli C, Luzi P, Alberti P, et al. Human papilloma virus infection and Ki-ras oncogene in paraffin-embedded squamous carcinomas of the cervix. Gynecol Obstet Invest 1993; 36: 185-188.
214. Hayashi Y, Hachisuga T, Iwasaka T, et al. Expression of ras oncogene product and EGF receptor in cervical squamous cell carcinomas and its relationship to lymph node involvement. Gynecol Oncol 1991; 40: 147-151.
215. Hale RJ, Buckley CH, Fox H, Williams J. Prognostic value of c-erbB-2 expression in uterine cervical carcinoma. J Clin Pathol 1992; 45: 594-596.
216. Kihana T, Tsuda H, Teshima S, et al. Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix. Cancer 1994; 73: 148-153.
217. Mitra AB, Murty VV, Pratap M, et al. ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Res 1994; 54: 637-639.
218. Oka K, Nakano T, Arai T. c-erbB-2 oncoprotein expression is associated with poor prognosis in squamous cell carcinoma of the cervix. Cancer 1994; 73: 664-671.
219. Holm R, Abeler VM, Skomedal H, Nesland JM. Overexpression of p53 protein and c-erbB-2 protein in small cell carcinoma of the cervix uteri. Zentralb Pathol 1993; 39: 153-156.
220. Kristensen GB, Holm R, Abeler VM, Trope CG. Evaluation of the prognostic significance of cathpepsin D, epidermal growth factor receptor and c-erbB-2 in early cervical squamous cell carcinoma: An immunohistochemical study. Cancer 1996; 78: 433-440.
221. Hale RJ, Buckley CH, Gullick WJ, et al. Prognostic value of epidermal growth factor receptor expression in cervical carcinoma. J Clin Pathol 1993; 46: 149-153.
222. Oka K, Nakano T, Arai T. Expression of cathpepsin D and epidermal growth factor receptor in stage III cervical carcinomas. Int J Gynecol Cancer 1997; 7: 122-126.
223. Hunt CR, Hale RJ, Armstrong C, Rajkumar T, Gullick WJ, Buckley CH. c-erbB-3 proto-oncogene expression in uterine cervical carcinoma. Int J Gynecol Cancer 1995; 5: 282-285.